ZimVie Inc. (Nasdaq: ZIMV), a global leader in life sciences and dental technology, has announced its financial results for the first quarter of 2025, highlighting improvements in profitability and operational performance despite a modest decline in revenue. The company reported Q1 net sales of $112.0 million, representing a 5.2% decrease from the same period last year, but also reported a significantly reduced net loss of $2.6 million—an $8.9 million improvement over Q1 2024.
Adjusted net income rose to $7.4 million, up from $2.2 million in the prior year’s quarter, with adjusted earnings per share (EPS) reaching $0.27. Adjusted EBITDA also showed notable growth, climbing to $17.6 million or 15.7% of net sales—up 520 basis points year-over-year.
CEO Vafa Jamali emphasized the company’s ongoing focus on operational efficiency and innovation in dental care.
Looking ahead, ZimVie reaffirmed its full-year 2025 guidance, projecting net sales between $445 million and $460 million, adjusted EBITDA of $65 million to $70 million, and adjusted EPS in the range of $0.80 to $0.95.
Click here to read the full press release for more information.
